Abstract In this study, we used extracellular matrix (ECM) gels and human bone allograft as matrix vehicles to deliver the sphingolipid growth factor FTY720 to rodent models of tibial fracture and a critical-sized cranial defect. We show that FTY720 released from injectable ECM gels may accelerate callous formation and resolution and bone volume in a mouse tibial fracture model. We then show that FTY720 binds directly to human trabecular allograft bone and releases over 1 week in vitro. Rat critical-sized cranial defects treated with FTY720-coated grafts show increases in vascularization and bone deposition, with histological and micro-computed topography (microCT) evidence of enhanced bone formation within the graft and defect void. Immunohistochemical analysis suggests that osteogenesis within FTY720-coated grafts is associated with reduced CD68 + macrophage infiltration and recruitment of CD29 + bone progenitor cells. Matrix binding of FTY720 thus represents a promising and robust bone regeneration strategy with potential clinical translatability.
Introduction
Treatment of musculoskeletal injuries carries an estimated annual burden of $127 billion in the USA [1] , of which $2.5 billion annually is spent on an average of 1.5 million autograft or allograft procedures [2] . The current gold standard of bone graft treatment, using autologous bone harvested from the iliac crest [3] , often is of insufficient mass to successfully repair the bone defect, with the secondary operation to obtain this tissue often causing donor site pain and morbidity [3, 4] . To meet the growing clinical need for bone reconstruction material and overcome the limited supply of autografts, bone allografts from donors have been used extensively to repair bone wounds. However, massive transplants using allografts experience a 30-60 % failure rate [5] and lose 50 % of their strength after 10 years [6] . Since vascularization and new bone formation are critical for stable incorporation of massive allografts, for example in large skull flaps commonly transplanted in wounded soldiers, there is a clinical need for new grafting technologies that enhance these endogenous reparative processes. In addition to annual costs of grafting procedures, $120 billion is spent to treat bone injuries that do not necessitate grafts, including 7.9 million annual bone fractures that carry a 10 % incidence of non-union [7] , which leads to improper healing and higher risk of re-injury. The development of an off-the-shelf acellular therapy that could meet both graftbased and graft-independent treatment of bone defects is clinically desirable.
Previously, we have demonstrated enhanced angiogenesis and regeneration in multiple injury models via local delivery of small molecules, particularly FTY720, a synthetic analog of sphingosine 1-phosphate (S1P) with agonist activity at S1P receptors S1P 1 and S1P [3] [4] [5] [8] [9] [10] [11] [12] [13] [14] . Oral administration of FTY720 is approved by the FDA to treat relapsing-remitting multiple sclerosis, with the predominant mechanism being Tiffany Wang and Jack Krieger contributed equally to this work. sequestration of lymphocytes in secondary lymph organs [15] . We have shown that sustained release of FTY720 from poly(lactic-co-glycolic-acid) (PLAGA)-based scaffolds promotes osseous regeneration and vascularization within critical-sized bone defects [10] [11] [12] [13] 16] . PLAGA is a widely used synthetic material for medical applications [17] [18] [19] [20] . Despite extensive literature applying PLAGA in animal models, and its status as a FDA-approved material, a small fraction of PLAGA-based technologies have progressed to clinical trials and only a select few are commercially available. One potential concern with using PLAGA is that its degradation on the nanoscale level may be more toxic than on the microscale level [21] .
Incorporating natural extracellular matrix (ECM) into biomaterial systems provides relevant biochemical and biophysical guidance cues to direct regeneration in bone, cartilage, nerve, and cardiac tissue [22] [23] [24] [25] [26] . Additionally, it is now a common practice in tissue engineering to exploit the capability of ECM to sequester and release tissue morphogens, but there are few strategies in the literature utilizing ECM to achieve controlled release of hydrophobic small molecules [27] [28] [29] . In the present study, we locally deliver FTY720 from ECM gel and human trabecular bone allograft to promote healing in models of endochondral and intramembranous bone regeneration, respectively. We show for the first time that FTY720 may accelerate fracture healing when released from an injectable murine basement membrane-based hydrogel (Matrigel®) plug in a murine tibial fracture model. We then show that FTY720 can adsorb to and release from the surface of devitalized human allograft bone matrix over 1 week in vitro. Direct coating of human trabecular bone grafts with FTY720 accelerates new bone deposition in a rat critical-sized cranial defect model, possibly due to accelerated vascularization, decreased recruitment of macrophages, and increased recruitment of bone progenitors.
Materials and methods

Welfare of animals
Animals were procured from Charles River Laboratories International (Wilmington, MA), and all applicable international, national, and institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the University of Virginia Animal Care and Use Committee.
Mouse tibial fracture model
Male BALB/c mice aged 10 weeks and weighing 20-25 g were anesthetized via intraperitoneal (i.p.) injections of ketamine (100 mg/kg) and xylazine (10 mg/kg) in saline. A sterile metal pin was inserted into the medullary canal to provide mechanical stability in the leg, and a fracture was created in the tibia using a Bonnarens-Einheron appartus as the impact device, where a 220-g weight was dropped from a height of 40 cm onto a blunt blade in contact with the tibia. Animals were treated with local injections of 0.1 mL Matrigel® (BD Biosciences, San Jose, CA), or Matrigel® containing low (1 nM) and high (10 nM) doses of FTY720 (Cayman Chemical, Ann Arbor, MI) which self-assembled into hydrogel plugs within the defect space at body temperature. Because the intramedullary metal pin interfered with micro-computed tomography (microCT) imaging, X-ray images were acquired weekly to track bone regeneration in the mouse tibial defect. Each week, mice were anesthetized via i.p. injections of ketamine (100 mg/kg) and xylazine (10 mg/kg) in saline and imaged using X-ray (exposure time =1 min at 30 eV). For microCT assessment of bone density and volume, mice were euthanized by CO 2 asphyxiation and their tibias were harvested at week 2 (n=3) and week 4 (n=3). The pin was removed, and the bone volume and bone density of the entire tibia were imaged using a VivaCT40 Scanner (SCANCO Medical, Brutusellen, Switzerland) at medium resolution using a voxel dimension of 21 μm. Tibia were embedded in paraffin and sections were prepared for hematoxylin and eosin (H&E) staining according to standard protocols.
Drug binding to hydroxyapatite
Surface adsorption of FTY720 to hydroxyapatite was visualized using fluorescent NBD-FTY720. Briefly, fragments of hydroxyapatite (3D Biotek, Hillsborough, NJ) were immersed in 10 μg/500 μL NBD-FTY720 (Cayman Chemical, Ann Arbor, MI) in methanol for 2 h and then rinsed once with PBS. Coated fragments were imaged using a Zeiss 710 NLO confocal microscope at 488-nm excitation and ×5 magnification (Zeiss, Thornwood, NY).
Drug release from human trabecular bone grafts
Allografts from research-consented donor were processed at LifeNet Health (Virginia Beach, VA). The mineralized cancellous bone allografts were processed with LifeNet's clinically proven Allowash XG® technology to remove >99 % of bone marrow and blood elements from the bone matrix, and also rendering the material sterile while maintaining biomechanical and biochemical properties. Processed allografts were received in the form of discs (8-mm radius, 1-mm thickness) and then cut in half into semicircular shape. For direct adsorption, bone grafts were gently vortexed for 4 h in a solution of 1.5 mg/0.6 mL FTY720 in methanol, or methanol only for control grafts. All bones were kept at 4°C for 24 h to dry and then lyophilized for 24 h to extract remaining solvent (Labconco Corp., Kansas City MO). The pre-loading and post-loading solutions were saved to measure FTY720 content in order to determine drug loading efficiency. For in vitro release, grafts were placed in vials containing 1 mL simulated body fluid (pH 7.2; 7.996 g NaCl, 0.35 g NaHCO 3 , 0.3 g KCl, 0.13 g KH 2 PO 4 , 0.095 g MgCl 2 , 0.278 g CaCl 2 , 0.06 g MgSO 4 in 1 L deionized water; all salts from Sigma-Aldrich, St. Louis, MO) with 4 % (w/v) fatty acid free bovine serum albumin (FAF-BSA) and maintained at 37°C with constant agitation. Each day, the bone was moved to a new vial with fresh solution. The solutions were taken through sphingolipid extraction, and sphingolipid content was measured using a Shimadzu UFLC High Performance Liquid Chromatograph (Columbia, MD) equipped with a Supelco Discovery C18, 5 μm connected to an ABI 4000 QTrap quadruple mass spectrometer (Applied Biosystems, USA). Briefly, D-erythro--Sphingosine (C-17 base) internal standard was added to each sample, sonicated for 10 min, and immediately incubated at 48°C for 16 h. After cooling to room temperature, KOH (0.2 mL, 1 M) was added and the solution was centrifuged at 10,000g for 10 min at 4°C. The supernatant was collected and dried to solid with nitrogen air flow and stored at −20°C.
Immediately before running the sample on the HPLC, the extraction residue was dissolved in methanol (0.3 mL) and centrifuged at 12,000g for 12 min at 4°C.
Rat cranial defect model
Female Sprague-Dawley rats aged 6-8 weeks and weighing ≈235 g underwent a critical-sized (8 mm) cranial defect surgery [12] . Briefly, animals were anesthetized via i.p. injection of ketamine (80 mg/kg) and xylazine (8 mg/kg) in saline. The dorsal skin was sterilized and a longitudinal incision was made over the dorsum of the skull over the sagittal suture through the skin and periosteum. The periosteum was elevated and reflected laterally. A 3-mm round burr was used to create a 8-mm defect in the bone under constant saline irrigation using a Hall High Speed Drill (CONMED, Linvatec, Largo, FL). The semicircular graft was placed underneath the periosteum, in direct contact with the parietal bone, centered on the sagittal suture and between the coronal and lamboid sutures. The periosteum and skin were sutured shut, and animals were given Ketoprofen (3 mg/kg SC) for 3 days as a post-operative analgesic. Rats were given free access to food and water and were monitored for complications or abnormalities. The animals received one of three treatments: no implant (empty defect), human trabecular semicircular bone graft (graft only), and FTY720-coated human trabecular semicircular bone graft (graft + FTY720). FTY720 was adsorbed directly to the bone grafts as previously described. Grafts were analyzed and distributed evenly across the two graft groups to control for graft size and density variation.
MicroCT analysis of the cranial defect
Rats were anesthetized via 2.5 % isoflurane gas and quantitatively analyzed for bone volume and bone density at weeks 0, 2, 4, 6, 10, and 12 (n=3 per time point). Scanning parameters in air were as follows: 38-μm voxel size, 55 kVp, 145 μA, medium resolution, 38.9-mm-diameter field of view, and 200-ms integration time (73-mGy radiation per scan). The threshold for bone evaluation was set at 481.3 mg hydroxyapatite (HA)/cm 3 . All scans maintained the same number of slices (≈260 slices) for the entire study, centered at the defect, with equal extension in the anterior and posterior directions from the edges of the defect. Regions of interest were drawn on the 2D image slices. In the cranial defect, the circular region of interest was bound by the physiological ridges that separate the parietal bone from the temporal bone, resulting in the inclusion of all the parietal bone through the slices.
Histological evaluation of the cranial defect
Tissue samples were harvested from the defect following terminal microCT imaging at week 12 and prepared for histology (n=3). Defect segments were decalcified, embedded in paraffin, and stored at −20°C. Prior to antibody staining, paraffin sections were de-waxed in ethanol and xylene solutions, and 5-μm sections were obtained on a microtome. Sections were prepared for H&E and Masson's Trichrome staining. Immunofluorescence staining was performed for the following targets: CD68 (primary: anti-rat CD68 (ABD Serotec, Raleigh, NC); secondary: AlexaFluor 594 (Life Technologies, Carlsbad, CA)), CD29 (anti-rat Alexafluor 647 CD29 (Biolegend, San Diego, CA)), and CD90 (primary: anti-rat CD90 (Abcam, Cambridge, MA); secondary: Dylight 594 (Invitrogen)). Samples were incubated with primary antibody overnight at 4°C, and secondary antibody for 1 h at room temperature with agitation. Images were acquired on a Zeiss LSM 700-405 confocal microscope (Zeiss, Thornwood, NY).
MICROFIL© analysis of vascularization in cranial defect
To assess vascular perfusion of the cranial defects in an independent study, rats treated with coated graft, control graft, or no graft were euthanized at week 2 and week 12 (n=3 per group per time point) and their vasculature was perfused with MICROFIL© (Flow Tech, Carver, MA) and imaged via microCT [12, 30, 31] . Briefly, rats were anesthetized with 2.5 % isoflurane gas and euthanized via intracardiac injection of pentobarbital (250 mg/kg), and the common carotid arteries were cannulated. The vasculature was flushed with 10 mL 2 % heparin-saline, then filled with 3 mL MICROFIL© injected simultaneously through both arteries, and allowed to set for 16 h at 4°C. The top of the skull was harvested, fixed, and decalcified. The samples were scanned in air with the following parameters: 21-μm voxel size, 45 kVp, 177 μA, medium resolution, 21.5-mm-diameter field of view, 200-ms integration time, and threshold of 164-1500 mg HA/cm 3 . Similar to bone analysis, 2D contours were drawn to enclose the area of interest, excluding the sagittal sinus because of its large volume compared to other microvasculature, and due to the large variance of its size between samples.
Statistical analysis
Data are presented as mean±s.e.m., and all statistical analyses were performed in GraphPad Prism 6. Bone volume and bone density in the cranial defect were compared between groups at each time point using unpaired t test. For mouse tibial fracture studies, n=3 per group per time point for each measurement was implemented. For rat cranial defect studies, n=3 per group per time point for each measurement was implemented.
Results
Local administration of FTY720 via ECM gel accelerates mouse tibial fracture repair Tibial fractures treated with low and high doses of FTY720 show no significant difference but a trend of increasing bone volume compared to vehicle control at week 2 as measured by microCT (Fig. 1a) . FTY720 appears to accelerate the formation and resolution of the fracture callous during the first 3 weeks, as indicated by the arrows in Fig. 1b . By week 4, tibias treated with low doses of FTY720 appear to achieve cortical union as indicated by representative microCT images and H&E staining (Fig. 1c, d ).
Sustained release of FTY720 from human bone allograft (Fig. 2a) . Quantification of pre-and post-loading solutions indicated an average loading of 193 μg FTY720/ mm 3 bone graft. FTY720 releases from the graft surface over the course of 1 week, with a burst release in the first 3 days and continued release over the remaining 4 days (Fig. 2c) .
Release of FTY720 from human trabecular bone allograft accelerates bone deposition in rat cranial defect
The surface of semicircular mineralized human trabecular allograft was directly loaded with FTY720 and placed within a rat critical-sized cranial defect. Since new bone formation is necessary to heal the critical-sized defect, changes in bone volume and bone density were assessed via microCT at weeks 0, 2, 4, 6, 10, and 12. Defects treated with FTY720-coated grafts show significantly higher bone volume by week 6 and bone density by week 10 (Fig. 3a, b) . Thus, direct adsorption of FTY720 to bone graft enhances osseous regeneration and engraftment potential. Bone volume shows an increasing trend for 12 weeks while bone density increases only until week 10, suggesting that bone deposition occurs preferentially outside the graft as opposed to within the graft. As shown in representative images in Fig. 3c, FTY720 enhances new bone deposition along the graft-host bone interface and in the void space.
Histological evaluation of osteogenesis and graft incorporation
Masson's trichrome staining was used to assess the tissue composition of key regions in the cranial defect at week 12. Qualitative evaluation of the entire graft region suggests that FTY720 stimulates robust tissue growth into the graft compared to uncoated graft which contains large areas devoid of tissue (Fig. 4a) . Host-derived osteoid was distinguished from graft-derived osteoid by the presence of pink cytoplasmic stain in regions of deep blue collagen coloration. Both graft groups show graft-host bridging formed by a mixture of fibrous tissue and nascent osteoid (Fig. 4b ). FTY720 appears to increase mature osteoid formation within the graft region and void region compared to control graft (Fig. 4c, d, asterisks) . H&E staining confirms the observation that FTY720 augments tissue ingrowth into the graft (Fig. 5) .
We have shown previously that local administration of FTY720 regulates the trafficking of inflammatory and osteogenic progenitor cells to sites of injury [9, 10, 32] . In order to assess the phenotype of cells recruited to the graft region, we performed immunohistochemical staining on defect tissue sections to visualize macrophages (CD68) and stromal populations enriched for osteogenic progenitor cells (CD29, CD90) [32] . As shown in Fig. 5 , FTY720 appears to modestly reduce accumulation of CD68 + macrophages and dramatically increase CD29 + cell infiltration into the graft region, with mild effect on CD90 + cell number.
Release of FTY720 from human trabecular bone allograft enhances early vascularization
Representative microCT images of MICROFIL© perfused animals show vascularity within the defect at weeks 2 and 12 ( Fig. 6 ). FTY720 appears to increase vascular density within the graft relative to control at week 2 ( Fig. 3a, b) . By week 12, vasculature appears more extensive in the control (Fig. 6 ).
Discussion
By exploiting the growth factor sequestration and release properties of natural ECM, FTY720 was locally delivered to a mouse tibial fracture via Matrigel® injection and promoted limited bone regeneration at the injury site. During endochondral osteogenesis such as fracture healing, the first step is Fig. 2 FTY720 binding to allograft bone. a Fluorescence microscopy of bone chips coated with NBD-labeled FTY720 as per methods. Bone chips without FTY720 show no signal (scale bar=1 mm). b Potential mechanism by which FTY720 binds to bone, via a transiently associated H+ (indicated by red dot and black arrow) to the NH2 group on the drug molecule interacting with the negatively charged bone surface. c Release of FTY720 from the bone graft surface is sustained for 1 week (n=6). Scale bar = 500 μm (Color figure online) creation of a callous that provides temporary mechanical stability while osteogenic cells migrate into the defect to remodel the callous into bone and achieve cortical union between the two ends of the defect [33, 34] . A recent study observed that systemic treatment with FTY720 after tibial fracture in mice did not improve healing parameters [35] , likely because the local effect of bone progenitor cell recruitment did not occur. We observe that callous formation and remodeling appear accelerated in FTY720-treated fractures (Fig. 1b) . It has been shown that FTY720 enhances BMP-2-mediated osteoblast differentiation [36] and that FTY720 significantly enhances SDF-1α-mediated chemotaxis of bone marrow stromal cells [32] , both of which could contribute regenerative cell populations to deposit and remodel the fracture callous.
We further exploited the ability of natural matrix to sequester and release FTY720 by coating the drug directly on the surface of human trabecular bone allograft, thus enabling investigation of an off-the-shelf, currently clinically used bone regeneration platform (allograft) with greater potential for clinical translation than polymer-based strategies. While in previous studies FTY720 release from cranial allograft was driven by degradation of the PLAGA vehicle, here drug release depends on diffusion from the surface of the mineralized bone matrix. We observe at least a 20-fold increase in FTY720 released from the directly coated bone grafts (43.0 μg at 7 days) compared to the PLAGA-coated grafts used previously (2.4 μg at 5 days), yet a smaller increase in bone volume [12] . It is possible that the dose of FTY720 in the present study exceeds the local concentration that optimally promotes vascularization and bone regeneration [12, 16] . Healing outcomes may be improved in future studies by reducing the FTY720 payload on the graft surface. Furthermore, differential release kinetics between PLAGA and direct adsorption strategies must be considered, since FTY720 released during PLAGA bulk degradation at later weeks may contribute to regeneration. In the PLAGA-coated allograft, FTY720 loading was limited by its saturation limit in PLAGA solution prior to coating the graft; here FTY720 loading is limited primarily by the surface area of the graft itself, which may allow for the higher loading efficiency. We speculate that electrostatic interactions between the FTY720 molecule, specifically the H+ that transiently associates with the amine group (critical micelle concentration of FTY720 + H+ = 75 μM) [37, 38] , and the slight negative charge of bone surface [39] , are responsible for FTY720 binding to the human allograft bone matrix (Fig. 2b) . Estimating the size of the FTY720 molecule to be 2900 Å 3 using lipid parameters (calculated from [40] ), theoretically, the bone surface can bind up to 7.9E10 FTY720 molecules/mm 2 (Fig. 2b) . Release continues for 1 week (Fig. 2c) , enabling sustained bioactivity of FTY720 in the wound healing environment. This loading strategy could be tuned in future studies by varying the initial drug concentration in the loading solution to create shorter release times at lower doses.
Histological evaluation of the cranial defect corroborates evidence of enhanced bone formation assessed by microCT. H&E staining shows robust tissue ingrowth into FTY720-coated grafts, and Masson's trichrome staining suggests that FTY720 enhances osteoid formation in the graft and void regions (Fig. 4c, d ). The effectiveness of FTY720 in this study may result from effects on inflammatory and osteogenic cell recruitment. Current understanding of the inflammatory cascade during wound healing suggests that both magnitude and phenotype of immune cell infiltration regulate healing outcomes [9, 10, 41] . Previous studies have shown that FTY720 enhances the recruitment of anti-inflammatory monocytes [9] and M2-like macrophages [10] associated with wound healing. Enhanced bone regeneration observed in FTY720-treated defects in the present study (Figs. 3 and 4) may be influenced by reduced inflammatory response, as evidenced by reduced CD68 + macrophage accumulation (Fig. 5) , or possibly a skewing of the population toward M2-like phenotypes. We stained for markers indicative of osteogenic progenitor cell populations and observed a higher frequency of CD29 + cells within FTY720-coated grafts, possibly indicating enhanced recruitment of endogenous progenitor cells to sites of new bone formation.
It is well documented that bone graft survival depends on host integration through neovascularization and bone graft resorption [42, 43] . In a clinical trial using a rh-BMP2-releasing sponge in human tibial fractures, 23 % of human subjects experienced treatment failure due to lack of graft integration [44] . Previous work has shown that FTY720 promotes growth of vascular networks when locally applied in a mouse dorsal skinfold window chamber [13, 14] and within cranial defect models [12, 16] . Vascular penetration into the graft reduces necrosis and ischemia thereby improving graft integration [45] . Here, we show that FTY720 released directly from the graft surface appears to increase vascularization within the graft at week 2 ( Fig. 6) , which may contribute to accelerated bone formation observed by weeks 6 and 10 (Fig. 3a, b) . By week 12, accelerated osteoid formation in the FTY720-treated defect may cause attenuation of the vascular network and thereby decrease vascular density compared to control. Although FTY720-treated defects do not have greater vascular investment and new bone deposition at week 12, the observed acceleration of these processes is likely to enhance graft performance, as Mah et al. showed that the rate of graft incorporation determines the efficacy of FDAapproved alloplastic bone materials in rat cranial defects [46] . Taken together, this study suggests that bone matrix binding of FTY720 may be used to direct bone allograft incorporation.
Conclusion
This study explored the use of natural ECM to sequester and release a sphingolipid growth factor (FTY720) to promote endogenous bone repair. This study provides preliminary evidence that local delivery of FTY720 via ECM gels or direct binding to human bone allografts may enhance healing outcomes in rodent models of tibial fracture and a critical-sized cranial defect, respectively. Removal of the polymer component of the drug delivery system in favor of ECM binding may potentially increase clinical translatability of this technology and further improve mineralized bone allograft incorporation and long-term graft survival.
